Mpac Lambert, a UK-based automation specialist, has announced the delivery of a fully automated production line for GlucoModicum’s Sofio sensor, a needle-free device designed for glucose monitoring. The new manufacturing system is capable of producing up to 21 million units per year and was developed following two years of industrial-scale proof-of-principle work.
The collaboration combines GlucoModicum’s magnetohydrodynamic (MHD) technology for needle-free sensing with Mpac Lambert’s experience in building custom automation solutions. This partnership aims to support the global rollout of the Sofio sensor by enabling high-volume and precise manufacturing.
Engineers at Mpac Lambert have created an assembly process that transforms flexible materials into complex components in less than one second per unit. The production line includes vision-guided die cutting, ultrasonic welding, enzyme dispensing, and downstream packaging to ensure quality and efficiency throughout the process. Both companies worked with specialists in welding and precision dispensing to develop an automation platform that can be expanded as demand increases.
Prior to full-scale construction, the teams produced tens of thousands of pilot units over two years to validate the system’s reliability and consistency.
“Taking Sofio to a global scale requires highly capable partners in many areas. Mpac Lambert’s expertise in high-volume and high-precision manufacturing has been a perfect fit for our needs, enabling a manufacturing platform inherently suited for high-volume, efficient production,” stated Harri Palomäki, Manufacturing & Ops Lead at GlucoModicum.
“Sofio represents a step change in glucose monitoring technology,” said Nathan Walsh, Sales Director at Mpac Lambert. “Our automation expertise has enabled GlucoModicum to take this innovation from lab-scale to commercial production, paving the way for accessible, needle-free glucose monitoring worldwide.”
